Nanomaterial interference with early human placenta: Sophisticated matter meets sophisticated tissues

Juch, Herbert; Nikitina, Liudmila; Debbage, Paul; Dohr, Gottfried; Gauster, Martin

doi:10.1016/j.reprotox.2013.05.011

Cited by 24 publications

(17 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As discussed above, studies have shown that even without the addition of targeting modalities, nanoparticles are retained in the placenta without fetal crossover, demonstrating the potential for treatment of placental diseases using NMDD agents -especially in the first trimester of pregnancy when the fetus is most vulnerable to exposure to xenobiotics [94]. However, despite the placenta's unrestricted access to maternal blood-borne drugs, only a relatively small fraction of maternally administered nontargeted nanoparticles are taken up by the placenta.…”

Section: Nanopharmaceuticals That Target the Placentamentioning

confidence: 99%

“…Though some studies have examined the toxicological effects of nanomaterials in pregnancy, and reviewed the methods by which to assess properties of engineered nanomaterials [117,118,119], there is a need for universal guidelines for nanotoxicological assessment in pregnancy. Toxic effects of nanomaterials at the maternal-fetal interface are often ignored and more comprehensive toxicological studies in this area are lacking, as has been stated previously by others in the field [94,120]. This issue is particularly problematic for studies on early pregnancy exposure, where our understanding of developmental toxicology and ability to devise pertinent models for preclinical toxicological studies is very limited [94].…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

“…Toxic effects of nanomaterials at the maternal-fetal interface are often ignored and more comprehensive toxicological studies in this area are lacking, as has been stated previously by others in the field [94,120]. This issue is particularly problematic for studies on early pregnancy exposure, where our understanding of developmental toxicology and ability to devise pertinent models for preclinical toxicological studies is very limited [94]. In order for NMDD agents to be adopted and accepted by the clinical obstetric community and their patients, clearly this barrier needs to be eliminated, so that formulations can be prescribed with absolute confidence knowing that the risks to mother and fetus are negligible and have been comprehensively evaluated.…”

Section: Conclusion and Future Perspectivementioning

confidence: 99%

See 2 more Smart Citations

Therapeutic and Safety Considerations of Nanoparticle-Mediated Drug Delivery in Pregnancy

Keelan

Leong

et al. 2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

Advances in nanotechnology have resulted in the design of effective, safe and tissue-selective nanocarriers for delivering therapeutics to treat malignancies, infections and other diseases. In pregnancy, nanoparticle-based drug formulations could have the potential to selectively target either the placenta and/or fetus, enabling 'fetal-friendly' drugs to be administered in pregnancy with minimal risk of off-target effects. A considerable amount of research has been carried out on maternal-placental-fetal nanoparticle uptake, transfer and toxicity using rodent and ex vivo models. However, the development of placental targeting strategies and the therapeutic evaluation of nanoformulations in pregnancy remains in its infancy. While some promising avenues are currently under investigation, much work is needed to bring the advantages of nanoparticle-based drug therapy in pregnancy to clinical reality.

show abstract

Section: Nanopharmaceuticals That Target the Placentamentioning

confidence: 99%

Section: Conclusion and Future Perspectivementioning

confidence: 99%

Section: Conclusion and Future Perspectivementioning

confidence: 99%

See 1 more Smart Citation

Therapeutic and Safety Considerations of Nanoparticle-Mediated Drug Delivery in Pregnancy

Keelan

Leong

et al. 2015

Nanomedicine (Lond.)

View full text Add to dashboard Cite

show abstract

“…Although animal-based studies are a time-consuming and expensive approach, they are still considered the most thorough means of investigating target organ toxicity, particularly for placental toxicity and reproductive toxicity. Female populations are vulnerable and deserve special attention because toxicity can impair female reproduction and fetal development ( Juch et al, 2013;Keelan, 2011). For example, an imbalanced and detrimental effect of TiO 2 nanoparticles was observed in the ovarian cells of mice, including changes in gene expression and in the regulation of the immune system, cell proliferation and many other vital functions of the ovary.…”

Section: Current In Vitro Modelsmentioning

confidence: 99%

Pluripotent stem cells: An in vitro model for nanotoxicity assessments

Handral

Tong

Islam

et al. 2016

J of Applied Toxicology

View full text Add to dashboard Cite

The advent of technology has led to an established range of engineered nanoparticles that are used in diverse applications, such as cell-cell interactions, cell-material interactions, medical therapies and the target modulation of cellular processes. The exponential increase in the utilization of nanomaterials and the growing number of associated criticisms has highlighted the potential risks of nanomaterials to human health and the ecosystem. The existing in vivo and in vitro platforms show limitations, with fluctuations being observed in the results of toxicity assessments. Pluripotent stem cells (PSCs) are viable source of cells that are capable of developing into specialized cells of the human body. PSCs can be efficiently used to screen new biomaterials/drugs and are potential candidates for studying impairments of biophysical morphology at both the cellular and tissue levels during interactions with nanomaterials and for diagnosing toxicity. Three-dimensional in vitro models obtained using PSC-derived cells would provide a realistic, patient-specific platform for toxicity assessments and in drug screening applications. The current review focuses on PSCs as an alternative in vitro platform for assessing the hazardous effects of nanomaterials on health systems and highlights the importance of PSC-derived in vitro platforms.

show abstract

“…Poulsen et al, 2015), but even more studies using only a single monolayer of choriocarcinoma cells like BeWo on a crude collagen matrix (e.g. Correia Carreira et al, 2015 or Ali et al, 2013), do not explain much about nano biokinetics in early human gestation (Juch et al, 2013). Especially, the critical period of organogenesis, when severe malformations can be induced, is not represented by such experiments, an essential teratologic issue worth mentioning in the discussions.…”

mentioning

confidence: 99%